Abstract
Atrophy of skeletal muscle is a serious consequence of numerous diseases, including cancer and AIDS. Successful treatments for skeletal muscle atrophy could either block protein degradation pathways activated during atrophy or stimulate protein synthesis pathways induced during skeletal muscle hypertrophy. This perspective will focus on the signalling pathways that control skeletal muscle atrophy and hypertrophy, including the recently identified ubiquitin ligases muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx), as a basis to develop targets for pharmacologic intervention in muscle disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Skeletal muscle gene expression dysregulation in long-term spaceflights and aging is clock-dependent
npj Microgravity Open Access 03 April 2023
-
Growth differentiation factor 11 induces skeletal muscle atrophy via a STAT3-dependent mechanism in pulmonary arterial hypertension
Skeletal Muscle Open Access 06 May 2022
-
TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
Cell Death & Disease Open Access 16 November 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Jagoe, R.T. & Goldberg, A.L. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr. Opin. Clin. Nutr. Metab. Care 4, 183–190 (2001).
Mosoni, L. et al. Lower recovery of muscle protein lost during starvation in old rats despite a stimulation of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 277, E608–616 (1999).
Musaro, A. et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genet. 27, 195–200 (2001).
Mitch, W.E. & Goldberg, A.L. Mechanisms of muscle wasting — the role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897–1905 (1996).
Tawa, N.E. Jr, Odessey, R. & Goldberg, A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 100, 197–203 (1997).
Goldspink, D.F., Garlick, P.J. & McNurlan, M.A. Protein turnover measured in vivo and in vitro in muscles undergoing compensatory growth and subsequent denervation atrophy. Biochem. J. 210, 89–98 (1983).
DeVol, D.L., Rotwein, P., Sadow, J.L., Novakofski, J. & Bechtel, P.J. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am. J. Physiol. 259, E89–E95 (1990).
Coleman, M.E. et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofibre hypertrophy in transgenic mice. J. Biol. Chem. 270, 12109–12116 (1995).
Musaro, A., McCullagh, K.J., Naya, F.J., Olson, E.N. & Rosenthal, N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400, 581–585 (1999).
Semsarian, C. et al. Skeletal muscle hypertrophy is mediated by a calcium-dependent calcineurin signalling pathway. Nature 400, 576–581 (1999).
Dunn, S.E., Burns, J.L. & Michel, R.N. Calcineurin is required for skeletal muscle hypertrophy. J. Biol. Chem. 274, 21908–21912 (1999).
Bodine, S.C. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biol. 3, 1014–1019 (2001).
Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biol. 3, 1009–1013 (2001).
Horsley, V. & Pavlath, G.K. Nfat: ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 156, 771–774 (2002).
Molkentin, J.D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998).
Serrano, A.L. et al. Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibres but not muscle growth. Proc. Natl Acad. Sci. USA 98, 13108–13113 (2001).
Dupont-Versteegden, E.E., Knox, M., Gurley, C.M., Houle, J.D. & Peterson, C.A. Maintenance of muscle mass is not dependent on the calcineurin–NFAT pathway. Am. J. Physiol. Cell Physiol. 282, C1387–C1395 (2002).
Naya, F.J. et al. Stimulation of slow skeletal muscle fibre gene expression by calcineurin in vivo. J. Biol. Chem. 275, 4545–4548 (2000).
Dunn, S.E., Chin, E.R. & Michel, R.N. Matching of calcineurin activity to upstream effectors is critical for skeletal muscle fibre growth. J. Cell Biol. 151, 663–672 (2000).
Murgia, M. et al. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nature Cell Biol. 2, 142–147 (2000).
Vivanco, I. & Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
Takahashi, A. et al. Myogenic Akt signalling regulates blood vessel recruitment during myofibre growth. Mol. Cell Biol. 22, 4803–4814 (2002).
Pallafacchina, G., Calabria, E., Serrano, A.L., Kalhovde, J.M. & Schiaffino, S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fibre type specification. Proc. Natl Acad. Sci. USA 99, 9213–9218 (2002).
Chen, W.S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203–2208 (2001).
Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 292, 1728–1731 (2001).
Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29–39 (1998).
Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signalling pathway. Genes Dev. 13, 3244–3258 (1999).
Huang, H. et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development 126, 5365–5372 (1999).
Wada, T. et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity. Mol. Cell. Biol. 21, 1633–1646 (2001).
Stiles, B. et al. Essential role of Akt-1/Protein kinase Bα in PTEN-controlled tumorigenesis. Mol. Cell. Biol. 22, 3842–3851 (2002).
Clement, S. et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409, 92–97 (2001).
Leevers, S.J., Weinkove, D., MacDougall, L.K., Hafen, E. & Waterfield, M.D. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 15, 6584–6594 (1996).
Zhang, H., Stallock, J.P., Ng, J.C., Reinhard, C. & Neufeld, T.P. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14, 2712–2724 (2000).
Montagne, J. et al. Drosophila S6 kinase: a regulator of cell size. Science 285, 2126–2129 (1999).
Pullen, N. et al. Phosphorylation and activation of p70s6k by PDK1. Science 279, 707–710 (1998).
Nave, B.T., Ouwens, M., Withers, D.J., Alessi, D.R. & Shepherd, P.R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344, 427–431 (1999).
Scott, P.H., Brunn, G.J., Kohn, A.D., Roth, R.A. and Lawrence J.C. Jr Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl Acad. Sci. USA 95, 7772–7777 (1998).
Reynolds, T.H.t., Bodine, S.C. & Lawrence, J.C. Jr. Control of Ser 2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem. 277, 17657–17662 (2002).
Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biol. 4, 648–657 (2002).
Tee, A.R. et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl Acad. Sci. USA 99, 13571–13576 (2002).
von Manteuffel, S.R., Gingras, A.C., Ming, X.F., Sonenberg, N. & Thomas, G. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc. Natl Acad. Sci. USA 93, 4076–4080 (1996).
Hara, K. et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272, 26457–26463 (1997).
Miron, M. et al. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nature Cell Biol. 3, 596–601 (2001).
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789 (1995).
Hinkle, R.T. et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the β2-adrenergic receptor. Muscle Nerve 25, 729–734 (2002).
Crespo, P., Xu, N., Simonds, W.F. & Gutkind, J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein βg subunits. Nature 369, 418–420 (1994).
Lecker, S.H. et al. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J. Clin. Invest. 104, 1411–1420 (1999).
Attaix, D., Combaret, L., Pouch, M.N. & Taillandier, D. Regulation of proteolysis. Curr. Opin. Clin. Nutr. Metab. Care 4, 45–9 (2001).
Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A. & Goldberg, A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl Acad. Sci. USA 98, 14440–14445 (2001).
Bodine, S.C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704–1708 (2001).
Centner, T. et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol. 306, 717–726 (2001).
McElhinny, A.S., Kakinuma, K., Sorimachi, H., Labeit, S. & Gregorio, C.C. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J. Cell Biol. 157, 125–136 (2002).
Acknowledgements
Thanks to L. S. Schleifer, P. R. Vagelos and G. D. Yancopoulos for enthusiastic support and critical guidance, and to the Regeneron community for their support. Thanks to colleagues at Procter & Gamble Pharmaceuticals for their support and for enthusiastic scientific collaboration, particularly R. Isfort. Particular thanks to G. Thurston for editing this manuscript. T. Stitt, M. Gonzalez, E. Latres, S. Stevens, M. Sleeman and K-L Lai also provided useful edits. Sincere apologies to scientific colleagues whose work was omitted from this perspective as a result of space constraints.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glass, D. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5, 87–90 (2003). https://doi.org/10.1038/ncb0203-87
Issue Date:
DOI: https://doi.org/10.1038/ncb0203-87
This article is cited by
-
Skeletal muscle gene expression dysregulation in long-term spaceflights and aging is clock-dependent
npj Microgravity (2023)
-
Growth differentiation factor 11 induces skeletal muscle atrophy via a STAT3-dependent mechanism in pulmonary arterial hypertension
Skeletal Muscle (2022)
-
From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome)
Current Obesity Reports (2022)
-
TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
Cell Death & Disease (2021)
-
Optimizing mechanical stretching protocols for hypertrophic and anti-apoptotic responses in cardiomyocyte-like H9C2 cells
Molecular Biology Reports (2021)